Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,

#1226 Follow Up of ≤ 2 cm Non Functioning Pancreatic NETs in Patients with MEN1 Treated with Conservative Approach

Introduction: There is a current trend for conservative treatment of non functioning pancreatic NET (NF-PNETs), ≤ 2 cm, in patients with MEN1, which are reported to be associated with low risk of metastasis and death.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Davi' M

Authors: Davì M, Cosaro E, Malpaga A, Butturini G, Ortolani S,

Keywords: Pancreatic neuroendocrine tumor, MEN1,

#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?

Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: davi' m

Authors: Davì M, Cingarlini S, Butturini G, Capelli P, Scarpa A,

Keywords: Everolimus, pancreatic NET, ectopic Cushing syndrome,

#102 Presentation and outcome of pancreaticoduodenal tumors in Multiple Endocrine Neoplasia type 1 (MEN 1) syndrome

Introduction: Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal dominant condition characterized by the development of parathyroid, pancreaticoduodenal endocrine and pituitaty tumors. Pancreaticduodenal endocrine tumors (PDETs) are a frequent manifestation of MEN 1, with a prevalence ranging from 30 to 75%, and represent a major cause of death in one-third of patients. There is continuing debate on their management, mainly on the optimal surgical strategy, due to their multicentricity and high recurrence rate.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Davi' M, Boninsegna L, Toaiari M, Scarpa A, Francia G,

Keywords: pancreaticoduodenal endocrine tumors, MEN 1,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.